Russell Investments Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Russell Investments Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-59,697	Closed	-$6.41M	–	3569
2023 Q1	$6.41M	Buy	59,697 +16,020	+37%	+$1.84M	0.01%	989
2022 Q4	$4.8M	Sell	43,677 -40,499	-48%	-$2.63M	0.01%	1113
2022 Q3	$4.96M	Buy	84,176 +45,466	+117%	+$2.08M	0.01%	1055
2022 Q2	$1.09M	Sell	38,710 -20,506	-35%	-$594K	﹤0.01%	1916
2022 Q1	$2.23M	Buy	+59,216	New	+$2.34M	﹤0.01%	1585

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Russell Investments Group's RXDX Position: Q2 2023 in Review

Russell Investments Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 59,697 shares — an estimated $6.41M sold.

Russell Investments Group first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $6.41M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Russell Investments Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Russell Investments Group sold 59,697 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $6.41M.
Russell Investments Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Russell Investments Group's Prometheus Biosciences, Inc. Common Stock position peaked at $6.41M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Russell Investments Group's 13F filing for Q2 2023, filed 10 Aug 2023.